包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
1mg * 5 | 电议 |
10mg | 电议 |
1mg * 10 | 电议 |
50mg | 电议 |
Erastin 是一种铁死亡诱导剂。 Erastin 结合并抑制电压依赖性阴离子通道 (VDAC2/VDAC3)。
Cell lines | 143B/BJeHLT/BJeLR/Calu-1/HT-1080 |
Preparation Method | Soluble in DMSO to 20 mM. |
Reaction Conditions | 10 μM, 72 h |
Applications | Erastin inhibited cystine uptake via system xc–and triggered ferroptosis in a variety of cellular contexts.(HT-1080: erastin IC50= 0.20 μM; Calu-1: erastin IC50= 0.14 μM) |
Animal models | BALB/c nude mice (colorectal cancer) |
Preparation Method | Soluble in DMSO to 20 mM |
Dosage form | 10 mg/kg, intravenous injection |
Applications | Erastin inhibited ALDH1 activity, and reduced sphere size and number in colorectal cancer cells. |
文献引用 | |
产品描述 | Erastin is a cell-permeable ferroptosis activatior and an antitumor agent that is selective for cell expressing oncogene RAS. Erastin induces ferroptosis through directly binding to VDAC2/3 to alter the permeability of the outer mitochondrial membrane, which decreases the rate of NADH oxidation. Besides exerting targeted effects, erastin also enhances chemotherapy, targeted therapy, and immunotherapy in certain cancer cells, suggesting a potential role of erastin in cancer cell treatment.[3] Erastin and its analogs specifically inhibited cystine uptake via system xc–, and triggered ferroptosis in a variety of cellular contexts and act much more potently than SAS. Moreover, Erastin was ~2500 times more potent than SAS as an inhibitor of system xc–function in both HT-1080 and Calu-1 cells (HT-1080: erastin IC50= 0.20 μM, SAS IC50= 450 μM; Calu-1: erastin IC50= 0.14 μM, SAS IC50= 460 μM).[1] Erastin, an inhibitor of SLC7A11, was found to hold a remarkably stronger cytotoxic effect on colorectal CSCs via in vitro and in vivo experiments. Besides, Erastin attenuated the chemoresistance of colorectal CSCs (colorectal cancer stem cells). For in vivo experiment, Erastin (10 mg/kg) was intravenously injected into mice with colorectal cancer every two days. It was found that Erastin inhibited ALDH1 activity, and reduced sphere size and number in colorectal cancer cells. [2] References: |